Drug intelligence / Profile preview

oxycodone + paracetamol

Development stage
Phase 4
Lead developer
Molteni Farmaceutici
Modality
Small Molecules
Administration
Oral
01

Overview

Depalgos is a fixed-dose combination small molecule analgesic drug containing oxycodone hydrochloride, a semi-synthetic mu-opioid receptor agonist, and paracetamol (acetaminophen), a non-opioid analgesic. It is primarily indicated for the management of moderate to severe acute pain, particularly in the postoperative setting following orthopedic or general surgery. Oxycodone acts as an agonist at mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. Paracetamol provides complementary analgesia, likely through the inhibition of prostaglandin synthesis in the central nervous system. Marketed in Italy by Molteni Farmaceutici, Depalgos is available in multiple strengths as film-coated and effervescent tablets, providing a synergistic approach to pain control by combining opioid and non-opioid mechanisms.

Brand names
Depalgos
Other names
oxycodone + acetaminophen
02

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on oxycodone + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxycodone + paracetamol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call